These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 10100404)
1. [Injectable progesterone in hormone replacement therapy in menopause]. Patacchiola F; Porzio G; Carta G; Mascaretti G; Palermo P; Silani S; Di Stefano LM; Moscarini M Clin Ter; 1998; 149(6):425-7. PubMed ID: 10100404 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of 17alpha-hydroxyprogesterone caproate in hormone replacement therapy. Agostini R; Casini ML; Costabile L; Paragona M; Marzano F; Unfer V Gynecol Endocrinol; 2005 Nov; 21(5):265-7. PubMed ID: 16373245 [TBL] [Abstract][Full Text] [Related]
3. Spacing-out of progestin--efficacy, tolerability and compliance of two regimens for hormonal replacement in the late postmenopause. Rabe T; Mueck AO; Deuringer FU; Vladescú E; Runnebaum B Gynecol Endocrinol; 1997 Dec; 11(6):383-92. PubMed ID: 9476087 [TBL] [Abstract][Full Text] [Related]
4. 17-alpha-Hydroxyprogesterone caproate and natural progesterone in assisted reproduction: a comparative study. Abate A; Brigandì A; Costabile L; Abate FG; Balzano E; Perino M Clin Exp Obstet Gynecol; 1997; 24(4):190-2. PubMed ID: 9478315 [TBL] [Abstract][Full Text] [Related]
5. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525 [TBL] [Abstract][Full Text] [Related]
6. Treatment of menopausal symptoms with three low-dose continuous sequential 17β-estradiol/progesterone parenteral monthly formulations using novel non-polymeric microsphere technology. Cortés-Bonilla M; Bernardo-Escudero R; Alonso-Campero R; Francisco-Doce MT; Hernández-Valencia M; Celis-González C; Márquez-Oñate R; Chedraui P; Uribe JA Gynecol Endocrinol; 2015 Jul; 31(7):552-9. PubMed ID: 26062108 [TBL] [Abstract][Full Text] [Related]
7. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone. Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347 [TBL] [Abstract][Full Text] [Related]
8. Effects of oral and transdermal hormone replacement therapy on internal carotid artery pulsatility indices in postmenopausal women. A prospective, randomized, comparative study. Sendağ F; Terek MC; Karadadaş N; Bilgin O J Reprod Med; 2001 Nov; 46(11):962-8. PubMed ID: 11762152 [TBL] [Abstract][Full Text] [Related]
9. Management of abnormal bleeding in women receiving hormone replacement therapy. Spencer CP; Cooper AJ; Whitehead MI BMJ; 1997 Jul; 315(7099):37-42. PubMed ID: 9233327 [No Abstract] [Full Text] [Related]
10. [Evaluation of hormone replacement therapy in the perimenopause by means of Menopause Rating Scale (MRS I)]. Hauser GA; Ernst U Zentralbl Gynakol; 1999; 121(11):530-6. PubMed ID: 10612221 [No Abstract] [Full Text] [Related]
11. Rapid increase in lumbar spine bone density in osteopenic women by high-dose intramuscular estrogen-progestogen injections. A preliminary report. Ulrich U; Pfeifer T; Lauritzen C Horm Metab Res; 1994 Sep; 26(9):428-31. PubMed ID: 7835827 [TBL] [Abstract][Full Text] [Related]
12. [Changes in reproductive hormones levels in the treatment of endometrial precancerous lesion with hydroxyprogesterone caproate]. Yang D; Zhu RL Zhonghua Fu Chan Ke Za Zhi; 1994 Apr; 29(4):205-6, 251. PubMed ID: 8082440 [TBL] [Abstract][Full Text] [Related]
13. Levonorgestrel-releasing intrauterine system as an adjunct to estrogen for the treatment of menopausal symptoms--a review. Peled Y; Perri T; Pardo Y; Kaplan B Menopause; 2007; 14(3 Pt 1):550-4. PubMed ID: 17224852 [TBL] [Abstract][Full Text] [Related]
14. Bhathena RK, Anklesaria BS, Ganatra AM, Pinto R. The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins. Br J Clin Pharmacol 1998 Feb; 45 (2): 170-172. Kneer-Aronoff C J Womens Health; 1998 Oct; 7(8):1054-5. PubMed ID: 10026007 [No Abstract] [Full Text] [Related]
15. [Hormone substitution by injectable preparations and skin implants]. Kuhl H Gynakologe; 1986 Dec; 19(4):241-7. PubMed ID: 3817596 [No Abstract] [Full Text] [Related]
16. [Double-blind method of the effect of menopause symptoms, lipid profile, and endometrial thickness of continuous therapy with estradiol valerate and medroxyprogesterone acetate]. Blümel JE; Roncagliolo ME; Gramegna G; Vásquez R; Estartus A; Tacla X; Brandt A Rev Chil Obstet Ginecol; 1994; 59(5):354-60. PubMed ID: 7569150 [TBL] [Abstract][Full Text] [Related]
18. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response. Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746 [TBL] [Abstract][Full Text] [Related]
19. The role of antiandrogens in hormone replacement therapy. Schneider HP Climacteric; 2000 Dec; 3 Suppl 2():21-7. PubMed ID: 11379383 [TBL] [Abstract][Full Text] [Related]
20. Effects of estrogen-progestin replacement therapy on plasma beta-endorphin levels in menopausal women. Ortega E; Cuadros JL; Gonzalez AR; Ruiz E Biochem Mol Biol Int; 1993 Apr; 29(5):831-6. PubMed ID: 8508135 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]